Towards defining antigenic targets for antibodies in multiple sclerosis

Towards defining antigenic targets for antibodies in multiple sclerosis

Bibliographic Details
Main Authors:	Littleton, E, Dreger, M, Palace, J, Vincent, A
Format:	Conference item
Published:	2006

Similar Items

Immunocapture and identification of cell membrane protein antigenic targets of serum autoantibodies.
by: Littleton, E, et al.
Published: (2009)

An approach to the identification of targets of autoantibodies in multiple sclerosis
by: Littleton, E, et al.
Published: (2004)

Serum autoantibodies against intracellular antigens in multiple sclerosis
by: Lily, O, et al.
Published: (2002)

Modafinil for multiple sclerosis fatigue: does it work?
by: Littleton, E, et al.
Published: (2010)

An audit of the use of Modafinil in clinical practice for the treatment of fatigue in multiple sclerosis patients
by: Littleton, E, et al.
Published: (2005)

Serum autoantibodies to oligodendrocyte and neuronal cell surface antigens in multiple sclerosis patients
by: Lily, O, et al.
Published: (2002)

Defining multiple sclerosis disease activity using MRI T2-weighted difference imaging.
by: Lee, M, et al.
Published: (1998)

The association of multiple sclerosis with bullous pemphigoid: is there a shared antigen response?
by: Taghipour, K, et al.
Published: (2012)

Targeting Antigen-Presenting Cells in Multiple Sclerosis Treatment
by: Piotr Szpakowski, et al.
Published: (2021-09-01)

Cytokine-defined B cell responses as Therapeutic Targets in Multiple Sclerosis
by: Rui eLi, et al.
Published: (2016-01-01)

Making the diagnosis of multiple sclerosis.
by: Palace, J
Published: (2001)

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.
by: Sørensen, P, et al.
Published: (2005)

The UK Multiple Sclerosis database.
by: Palace, J, et al.
Published: (1999)

Targeting Dendritic Cells with Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases
by: Courtney A. Iberg, et al.
Published: (2020-06-01)

New and old treatments for multiple sclerosis.
by: Palace, J
Published: (1998)

Targeted Therapy of Multiple Sclerosis: A Case for Antigen-Specific Tregs
by: Yiya Zhong, et al.
Published: (2024-05-01)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
by: Sørensen, P, et al.
Published: (2010)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
by: Clerico, M, et al.
Published: (2008)

Guidelines for differential diagnosis of suspected multiple sclerosis.
by: Palace, J
Published: (2009)

Modifying disability in progressive multiple sclerosis.
by: Palace, J, et al.
Published: (2014)

Modifying disability in progressive multiple sclerosis
by: Palace, J, et al.
Published: (2014)

New treatments and azathioprine in multiple sclerosis.
by: Palace, J, et al.
Published: (1997)

A novel sensitive assay for aqueporin-4 antibodies (NMO-IgG)
by: Waters, P, et al.
Published: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
by: Clerico, M, et al.
Published: (2008)

The prevalence of IgG antibodies against milk and milk antigens in patients with multiple sclerosis
by: Rittika Chunder, et al.
Published: (2023-07-01)

Multiple sclerosis associated with Leber's Hereditary Optic Neuropathy.
by: Palace, J
Published: (2009)

Outer membrane protein size and LPS O-antigen define protective antibody targeting to the Salmonella surface
by: C. Coral Domínguez-Medina, et al.
Published: (2020-02-01)

Single tumor imaging with multiple antibodies targeting different antigens
by: Yujing Sun, et al.
Published: (2012-04-01)

Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study.
by: Lily, O, et al.
Published: (2004)

Outer membrane protein size and LPS O-antigen define protective antibody targeting to the Salmonella surface
by: Domínguez-Medina, CC, et al.
Published: (2020)

Attempts to define Plasmodium Falciparum antigens with human monoclonal antibodies
by: C. Desgrandes, et al.
Published: (1986-01-01)

Defining a role for laquinimod in multiple sclerosis
by: Bernd C. Kieseier
Published: (2014-07-01)

Thalamic neurodegeneration in multiple sclerosis.
by: Cifelli, A, et al.
Published: (2002)

Running a mitoxantrone service for multiple sclerosis
by: Craner, M, et al.
Published: (2006)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
by: Clerico, M, et al.
Published: (2006)

MONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENT
by: E. V. Popova
Published: (2017-05-01)

Multiple sclerosis lesions: insights from imaging techniques.
by: Tomassini, V, et al.
Published: (2009)

Interleukin-17 expression in multiple sclerosis
by: Tzartos, J, et al.
Published: (2006)

Monoclonal antibodies in development in multiple sclerosis
by: J. Sastre-Garriga, et al.
Published: (2011-11-01)

The Role of Antibodies in the Pathogenesis of Multiple Sclerosis
by: Xiaoli Yu, et al.
Published: (2020-10-01)